Table 1.
Reported cases of clear cell carcinoma in young women without DES exposure; literature search during 2000–2016 period.
| Age (years old) | FIGO stage | Tumor size (cm) | Treatment | Follow-up period (months) | Outcome | |
|---|---|---|---|---|---|---|
| Seki et al. (2003) | 18 | Ib2 | 6 | NAC (mitomycin etoposide carboplatin) RH, BPLND | 48 | Free of disease |
| Ding et al. (2004) | 19 | Ib2 with pelvic node metastasis | 8 | Conization, BPLND, BOT Adjuvant RT | 24 | Free of disease |
| Ahrens et al. (2005) | 6 | Ib1 | 2 | Partial trachelectomy | 12 | Free of disease |
| Yabushita et al. (2008) | 17 | Ib1 | 1.5 | RH, BPLND | 24 | Free of disease |
| Baykara et al. (2014) | 16 | Ib1 | 3 | RH, BPLND, adjuvant CT (carboplatin, paclitaxel) | 24 | Free of disease |
| 14 | Ib2 | 6 | TAH BSO BPLND | 24 | Free of disease | |
| Choi (2013) | 15 | IIA pelvic LN metastasis | 7 | RH BPND BOT adjuvant CT (carboplatin, paclitaxel) | 6 | Free of disease |
| Ashton et al. (2013) | 18 pregnant 33 week | Ib1 | 0.6 | Cesarean section at 34 weeks then RH BPND BSO | 36 | Free of disease |
| Andi Asri et al. (2016) | 10 | Ib2 | unknown (pelvic mass 14 cm) | RH, BPLND adjuvant CT (carboplatin + paclitaxel) | 3 | Recurrent in lung and brain |
DES, diethylstilbestrol; TAH, total abdominal hysterectomy; RH, radical hysterectomy; BSO, bilateral salpingoophorectomy; BPLND, bilateral pelvic node dissection; BOT; bilateral ovarian transposition; NAC, neoadjuvant chemotherapy; CT, chemotherapy; RT, radiotherapy.